|
|
Vaccine Detail
|
Telomerase: 540-548 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Telomerase: 540-548 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007184
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TERT
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Plasmid pGFP/Ub was used to carry minigenes encoding hTERT-derived peptides (Ayyoub et al., 2001).
- Description: This is for Brain Cancer and Sarcoma (NCT00069940). A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development; its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells (NCI04) (Ayyoub et al., 2001; NCIT_C2640).
|
| Host Response |
|
|
| References |
Ayyoub et al., 2001: Ayyoub M, Migliaccio M, Guillaume P, Liénard D, Cerottini JC, Romero P, Lévy F, Speiser DE, Valmori D. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. European journal of immunology. 2001; 31(9); 2642-2651. [PubMed: 11536162].
NCIT_C2640: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2640]
NCT00069940: [https://clinicaltrials.gov/show/NCT00069940/]
|
|
